Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
0.8058
-3.5542 (-81.52%)
Streaming Delayed Price
Updated: 11:59 AM EST, Dec 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 17, 2022
Gainers Creative Medical Tech (NASDAQ:CELZ
Via
Benzinga
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
↗
February 14, 2022
According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54...
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update
February 11, 2022
Via
Investor Brand Network
Recap: VistaGen Therapeutics Q3 Earnings
↗
February 10, 2022
VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 10, 2022
↗
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
Why VistaGen Therapeutics' Stock Is Trading Higher Today
↗
May 20, 2021
VistaGen Therapeutics (NASDAQ:VTGN) shares are tradin...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call
February 07, 2022
Via
Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18
November 16, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights
November 11, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update
November 04, 2021
Via
Investor Brand Network
VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
↗
October 14, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
October 14, 2021
Via
Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity
October 05, 2021
Via
Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
August 26, 2021
Gainers MorphoSys (NASDAQ:MOR) stock move...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
August 13, 2021
Gainers Cellect Biotechnology (NASDAQ:APOP
Via
Benzinga
Recap: VistaGen Therapeutics Q1 Earnings
↗
August 12, 2021
Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the...
Via
Benzinga
Looking Into VistaGen Therapeutics's Return On Capital Employed
↗
July 13, 2021
In Q4, VistaGen Therapeutics (NASDAQ:VTGN) posted sales of $441.90 thousand. Earnings were up 17.36%, but VistaGen Therapeutics still reported an overall loss of $6.22 million....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 08, 2021
Gainers Dare Bioscience (NASDAQ:DARE) sto...
Via
Benzinga
VistaGen Therapeutics Insights: Return On Capital Employed
↗
July 06, 2021
During Q4, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $441.90 thousand. Despite a 17.36% in earnings, the company posted a loss of $6.22 million. In Q3, VistaGen...
Via
Benzinga
Stocks That Hit 52-Week Highs On Friday
↗
July 02, 2021
Before 10 a.m. ET Friday, 146 stocks hit new 52-week highs. Interesting Facts: The largest company by market cap to set a new 52-week high was Microsoft (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
↗
July 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Why VistaGen Therapeutics Stock Jumped Today
↗
June 30, 2021
Investors liked the drugmaker's corporate update.
Via
The Motley Fool
VistaGen Therapeutics: Q4 Earnings Insights
↗
June 29, 2021
Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 328.57%...
Via
Benzinga
Earnings Scheduled For June 29, 2021
↗
June 29, 2021
Companies Reporting Before The Bell • GreenPower Motor Co (NASDAQ:GP) is likely to report earnings for its fourth quarter. • Tsakos Energy Navigation (NYSE:TNP)...
Via
Benzinga
72 Biggest Movers From Yesterday
↗
July 01, 2021
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...
Via
Benzinga
Topics
Initial Public Offering
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 22, 2021
Gainers Tenax Therapeutics (NASDAQ:TENX) ...
Via
Benzinga
60 Biggest Movers From Yesterday
↗
May 27, 2021
Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday. Flywire Corporation (NASDAQ: FLYW) gained 46.3% to settle at $35.10 after the company priced...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 26, 2021
Gainers Zosano Pharma (NASDAQ:ZSAN) stock...
Via
Benzinga
VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B
↗
May 26, 2021
VistaGen Therapeutics Inc (NASDAQ: VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD). PH94B is an...
Via
Benzinga
60 Biggest Movers From Yesterday
↗
May 21, 2021
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today